CIDEB siRNA Trial Reports Lower Liver Fat in MASLD Patients
A single administration reduced liver fat by up to 80%, with reductions sustained through 36 weeks. First-in-human trial data were presented at AASLD and published in The New England Journal of Medicine.
Story updates
09:02:05 PM UTC
SquawkNews
In a first-in-human Phase 1/2 trial, a single CIDEBsiRNA dose reduced liver fat by up to 80% through week 36 and improved liver injury markers in adults with MASLD. The release gives no prior-period comparison.Material DetailsContext by AI AnalystThis is an early clinical signal for an investigatio…